[1]万鼎铭)△,金婷),邵运丽),等.异基因造血干细胞移植治疗bcr/abl融合基因阳性急性白血病的临床疗效观察[J].郑州大学学报(医学版),2013,(03):394.
 WAN Dingming),JIN Ting),SHAO Yunli),et al.Effect of allogeneic hematopoietic stem cell transplantation on acute leukemia with bcr/abl fusion genepositive[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(03):394.
点击复制

异基因造血干细胞移植治疗bcr/abl融合基因阳性急性白血病的临床疗效观察
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2013年03期
页码:
394
栏目:
应用研究
出版日期:
2013-06-20

文章信息/Info

Title:
Effect of allogeneic hematopoietic stem cell transplantation on acute leukemia with bcr/abl fusion genepositive
作者:
万鼎铭1)金婷1)邵运丽2)张素平1)石聪聪1)张媛1)李丽1)边志磊1)周雪芳1)
1)郑州大学第一附属医院血液科 郑州 450052
2)河南大学第一附属医院血液肿瘤科 开封 475000
Author(s):
WAN Dingming1) JIN Ting1) SHAO Yunli2) ZHANG Suping1) SHI Congcong1) ZHANG Yuan1) LI Li1) BIAN Zhilei1) ZHOU Xuefang1)
1)Department of Hematology, the First Affiliated Hospital,Zhengzhou University, Zhengzhou 450052
2)Department of Hematology and Oncology, the First Affiliated Hospital,Henan University, Kaifeng 475000
关键词:
异基因造血干细胞移植bcr/abl融合基因急性白血病酪氨酸激酶抑制剂
Keywords:
allogeneic hematopoietic stem cell transplantation bcr/abl fusion gene acute leukemia tyrosine kinase inhibitor
分类号:
R551.3
摘要:
摘要目的:观察异基因造血干细胞移植治疗bcr/abl融合基因阳性急性白血病的临床疗效。方法:对MICM分型确诊的18例bcr/abl融合基因阳性急性白血病患者,采用化疗或加用酪氨酸激酶抑制剂达完全缓解后行异基因造血干细胞移植术。结果:18例行异基因造血干细胞移植术后,均获得造血及免疫功能重建。9例无病存活;1例复发,经治疗后再次达完全缓解;8例死亡,其中因复发死亡3例,移植相关死亡5例。2 a无病生存率为(31.6±14.0)%,2 a总生存率为(48.0±13.9)%;中位无病生存时间(9.0±3.1)个月,中位总生存时间(18.0±8.0)个月。结论:异基因造血干细胞移植是目前治愈bcr/abl融合基因阳性急性白血病的惟一有效手段,联合酪氨酸激酶抑制剂能有效提高长期生存率。
Abstract:
AbstractAim: To observe the effect of allogeneic hematopoietic stem cell transplantation(AHSCT) on acute leukemia with bcr/abl fusion genepositive. Methods:A total of 18 cases of MICMtyping confirmed acute leukemia with positive bcr/abl fusion gene were given AHSCT, after complete remission treated by chemotherapy or combined with tyrosine kinase inhibitors. Results: All the patients acquired hematopoietic and immune reconstitution after AHSCT, among whom 9 cases had diseasefree survival;1 case relapsed and achieved complete remission again after treatment; and the other 8 cases died, including 3 cases of relapse and 5 cases of transplantation related mortality. The rate of 2year diseasefree and overall survival were(31.6±14.0)% and (48.0±13.9)%, respectively; the median diseasefree survival time was(9.0±3.1) months, and the median overall survival time was (18.0±8.0) months, respectively. Conclusion: AHSCT is currently the only effective means of curing bcr/abl fusion genepositive acute leukemia;AHSCT combined with tyrosine kinase inhibitor can significantly improve longterm survival.

参考文献/References:

[1]费新红,武淑兰,孙瑞娟,等. 12例Ph染色体和BCR/ABL阳性急性髓系白血病临床分析[J].中国实验血液学杂志,2012,20(3):545
[2]Thomas D. Childhood Philadelphia chromosomepositive B lymphoblastic leukaemia[J]. Lancet Oncol,2012,13(9):860
[3]Bennour A, Ouahchi I, Moez M, et al. Comprehensive analysis of BCR/ABL variants in chronic myeloid leukemia patients using multiplex RTPCR[J]. Clin Lab,2012,58(5/6):433
[4]Soupir CP, Vergilio JA, Dal Cin P, et al. Philadelphia chromosomepositive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis [J]. Am J Clin Pathol,2007,127(4):642
[5]鲍立,江滨,黄晓军,等.Ph阳性急性淋巴细胞白血病的临床研究[J].中华血液学杂志,2005,26(1):31
[6]Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms[J]. Chem Biol Interact,2010,184(1/2):16
[7]万鼎铭,康轶青,孙慧,等.改良BU/CY预处理方案行异基因造血干细胞移植治疗恶性血液病的临床研究[J].中国实用内科杂志,2009, 29(7):648
[8]肖志坚.急性白血病化疗药物所致肝损害的诊治[J].中国实用内科杂志,2011,31(12):910
[9]万鼎铭,邵运丽,秦童,等. HLA单倍体与全相合异基因造血干细胞移植治疗恶性血液病[J].中国组织工程研究,2012,16(32):6076
[10]Thomas E, Storb R, Clift RA, et al. Bonemarrow transplantion (first of two parts) [J]. N Engl J Med,1975,292(16):832
[11]明亮.Ph染色体阳性急性髓系白血病患者细胞遗传学和免疫表型分析[J].郑州大学学报:医学版,2007,42(5):948
[12]邱镜滢, 朱伟, 张艳,等. Ph染色体阳性急性白血病细胞遗传学及临床研究 [J].中国实验血液学杂志,2005,13(3):358
[13]张越峰,陈志妹,楼基余,等.Ph染色体阳性的成人急性淋巴细胞白血病临床分析[J].中华血液学杂志,2011,32(12):814
[14]Kroger N, Krüger W, WackerBackhaus G, et al. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosomepositive acute lymphoblastic leukemia[J]. Bone Marrow Transplant,1998,22(11):1029
[15]Lee S, Kim YJ,Min CK,et al. The effect of firstline imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia[J].Blood,2005,105(9):3449
[16]Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for highrisk Philadelphia chromosomepositive leukemia[J]. Blood,2007,109(7):2791

相似文献/References:

[1]喻凤宽,符粤文,周健,等.异基因造血干细胞移植中嵌合体的STRPCR定量检测[J].郑州大学学报(医学版),2012,(03):373.
 YU Fengkuan,FU Yuewen,ZHOU Jian,et al.A quantitative detection of graft chimerism following allogeneic hematopoietic stem cell transplantation by PCRSTR[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2012,(03):373.
[2]万鼎铭△,周雪芳,谢新生,等.异基因造血干细胞移植后肠球菌相关性腹泻的临床分析[J].郑州大学学报(医学版),2014,(02):284.
 WAN Dingming,ZHOU Xuefang,XIE Xinsheng,et al.Clinical analysis of enterococcus associated diarrhea in patients received allogeneic hematopoietic stem cell transplantation[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(03):284.

备注/Memo

备注/Memo:
△男,1963年5月生,博士,教授,主任医师,研究方向:血液病和造血干细胞移植的基础和临床,Email:wwddmm@vip.sina.com
更新日期/Last Update: 2013-07-03